Sunflower Pharmaceutical Group Co.,Ltd

002737

CNE100001WT7

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
29.15 ^CNY	-1.15%		-0.72%	+12.20%

May. 06	China Grants Marketing Authorization to Sunflower Pharma's Electrolyte Powder for Constipation	MT
Apr. 26	Sunflower Pharmaceutical Group Co.,Ltd Announces Profit Distribution Proposal for 2023	CI

Tranche Update on Sunflower Pharmaceutical Group Co.,Ltd's Equity Buyback Plan announced on December 24, 2020.

December 13, 2021 at 11:00 am EST

From October 1, 2021 to December 13, 2021, the company has repurchased 0 shares, representing 0% for CNY 0 million. With this, the company has completed the repurchase of 3,838,503 shares, representing 0.66% for CNY 56.33 million under the buyback announced on December 24, 2020.

Latest news about Sunflower Pharmaceutical Group Co.,Ltd

China Grants Marketing Authorization to Sunflower Pharma's Electrolyte Powder for Constipation	May. 06	MT
Sunflower Pharmaceutical Group Co.,Ltd Announces Profit Distribution Proposal for 2023	Apr. 26	CI
Sunflower Pharmaceutical Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Chinese Drug Regulator Accepts Application of Sunflower Pharma's Unit for Fexofenadine Hydrochloride Oral Suspension	Feb. 19	MT
Sunflower Pharmaceutical Group Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-25	CI
Sunflower Pharma Buys Local Drug Distributor for 2.3 Million Yuan	23-09-04	MT
Sunflower Pharmaceutical Group Co.,Ltd agreed to acquire Hainan Huihai Pharmaceutical Co., Ltd. from Tonghua Huikang Biopharmaceutical Co., Ltd. and Kang Jia for CNY 2.3 million	23-09-01	CI
Sunflower Pharmaceutical Group Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-24	CI
Sunflower Pharmaceutical Group Co.,Ltd Announces Final Cash Dividend on Share A for 2022, Payable on June 7, 2023	23-05-30	CI
Sunflower Pharmaceutical Group Co.,Ltd Approves 2022 Profit Distribution Plan	23-05-08	CI
Sunflower Pharmaceutical Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Sunflower Pharmaceutical Group Co.,Ltd Announces Profit Distribution Proposal for 2022	23-04-12	CI
Sunflower Pharmaceutical Group Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-11	CI
Sunflower Pharmaceutical Group Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-26	CI
Sunflower Pharmaceutical Group Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-09	CI
Sunflower Pharmaceutical Group Co.,Ltd Announces 2021 Final Profit Distribution Plan to Be Implemented on A Shares, Payable on 02 June 2022	22-05-25	CI
Sunflower Pharmaceutical Group Co.,Ltd Approves 2021 Profit Distribution Plan	22-05-16	CI
Sunflower Pharmaceutical Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-27	CI
Sunflower Pharmaceutical Group Co.,Ltd Proposes Final Cash Dividend for the Year 2021	22-04-22	CI
Sunflower Pharmaceutical Group Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-21	CI
Tranche Update on Sunflower Pharmaceutical Group Co.,Ltd's Equity Buyback Plan announced on December 24, 2020.	21-12-13	CI
Sunflower Pharmaceutical Group Co.,Ltd's Equity Buyback announced on December 24, 2020, has expired with 3,838,503 shares, representing 0.66% for CNY 56.33 million.	21-12-12	CI
Sunflower Pharmaceutical Group Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-27	CI
Tranche Update on Sunflower Pharmaceutical Group Co.,Ltd's Equity Buyback Plan announced on December 24, 2020.	21-10-11	CI
Sunflower Pharmaceutical Group Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-25	CI

Chart Sunflower Pharmaceutical Group Co.,Ltd

Duration

Period

Chart Sunflower Pharmaceutical Group Co.,Ltd

More charts

Company Profile

SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD is a China-based company principally engaged in the research, development, manufacture and sale of Chinese patent drugs, chemical drugs, biopharmaceuticals and health products. The Company provides drugs in six categories, including digestive medicine, pediatric medicine, gynecological medicine, rheumatoid bone medication, breathing cold medication and cardiovascular drugs. The Companyâs main products include Weikangling capsules, liver tablets, hyperactivity cough oral liquid for children use, pediatric Huatanzhike particles, Kangfu anti-inflammatory suppository and pediatric paracetamol particles, among others. The Company distributes its products in domestic market.

Sector

Pharmaceuticals

Calendar

2024-05-30 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD	+12.20%	2.36B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+21.63%	44.11B
OTSUKA HOLDINGS CO., LTD.	+23.03%	22.71B
SANDOZ GROUP AG	+18.22%	15.15B
CIPLA LIMITED	+12.66%	13.56B
ZYDUS LIFESCIENCES LIMITED	+60.18%	12.7B
ONO PHARMACEUTICAL CO., LTD.	-10.02%	6.84B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+12.92%	5.63B

Generic Pharmaceuticals

Sunflower Pharmaceutical Group Co.,Ltd

Equities

002737

CNE100001WT7

Pharmaceuticals

Tranche Update on Sunflower Pharmaceutical Group Co.,Ltd's Equity Buyback Plan announced on December 24, 2020.

Latest news about Sunflower Pharmaceutical Group Co.,Ltd

Chart Sunflower Pharmaceutical Group Co.,Ltd

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Generic Pharmaceuticals